IASO208 receives FDA IND clearance as first China-originated lentiviral in vivo CAR-T
AI Summary- IASO Bio received FDA clearance for the IASO208 IND application.
- 11 patients have received IASO208 in an ongoing Chinese investigator-initiated study.
- IASO208 is expected to enter a U.S. Phase 1b study for relapsed/refractory B-cell lymphoma.